The First Center Hospital of Tianjin

Tianjin, China

The First Center Hospital of Tianjin

Tianjin, China
SEARCH FILTERS
Time filter
Source Type

Wu D.,The First Center Hospital of Tianjin | Shen Z.-Y.,The First Center Hospital of Tianjin | Zhang Y.-M.,The First Center Hospital of Tianjin | Wang J.,The First Center Hospital of Tianjin | And 3 more authors.
BMC Cancer | Year: 2015

Background: Liver transplantation is a treatment option for combined hepatocellular and cholangiocellular carcinoma (cHCC-CC) but its prognostic significance remains unclear. The present study aimed to evaluate the therapeutic effects of liver transplantation on cHCC-CC and analyze the clinicopathological factors affecting prognosis. Methods: Retrospective analysis of the clinicopathological data of a case series of 21 patients with cHCC-CC who underwent orthotopic liver transplantation from April 2000 to April 2011 was performed. Cumulative survival rate and tumor-free survival rate were calculated using the Kaplan-Meier method followed by the log-rank test. Results: The operative survival rate of the 21 patients was 100%; the 30 day mortality was 4.8% (1/21) and 90-day mortality was 9.5% (2/21); 1-, 2-, 3-, and 5-year overall cumulative survival rates were 64%, 47%, 39%, and 39%, respectively; and the corresponding cumulative tumor-free survival rates were 64%, 37%, 30%, and 30%, respectively. Cumulative tumor diameter, lymph node metastasis, macroscopic portal vein tumor thrombus, and mixed states according to Allen typing were identified as the primary influencing factors of poor prognosis (all P<0.05). Conclusion: Liver transplantation may be an effective therapeutic method for the treatment of cHCC-CC. Strict screening of potential liver transplantation candidates with cHCC-CC can help reduce the risks of tumor recurrence and metastasis. © 2015 Wu et al.; licensee BioMed Central.


Zhang X.-X.,Tianjin University of Commerce | Li Y.,Tianjin University of Commerce | Wang S.-Y.,Tianjin University of Commerce | Wang Y.-Y.,The First Center Hospital of Tianjin | And 6 more authors.
Applied Biochemistry and Microbiology | Year: 2015

Recent studies have shown that the human colostrum and milk are a continuous supply of commensal, mutualistic and/or potentially probiotic bacteria to the infant gut. The diversity of complex bacterial communities in human milk can be used for the screening of novel bacteria with a potential interest for industry. Here, a protease-producing strain R75E was isolated from human colostrum and identified as Bacillus cereus based on its morphological, physiological and biochemical properties and molecular characterization. B. cereus R75E was found to produce 2 types of proteases with molecular weights of 106 and 95 kDa. Tandem mass spectrometry analysis has shown that both of these proteases belong to the 965-aa collagenase (GenBank accession no. KDB42252.1) of B. cereus. By PCR, the B. cereus R75E collagenase was identified just in the same DNA sequence as 965-aa collagenase. Its high sensitivity to EDTA verified that the enzyme is metalloprotease as expected by protein domain analysis. The present collagenase demonstrated high efficiency for the degradation of the native type I collagen, suggesting its potential applications to the degradation of animal organisms. © 2015, Pleiades Publishing, Inc.


PubMed | the First Center Hospital of Tianjin
Type: Comparative Study | Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association | Year: 2015

The question of which treatment should be preferred for the treatment of Graves disease is debatable, and pairwise meta-analyses could not obtain hierarchies of these treatments. Our intention was to integrate the evidence to provide hierarchies of the comparative efficacy of 4 treatments (radioiodine, radioiodine+prednisone, antithyroid drugs and surgery).We conducted a Bayesian-framework network meta-analysis of randomized controlled trials (RCTs) to compare 4 treatments in patients with Graves disease. The eligible RCTs were identified by searching Amed, the British Nursing Index, Embase, PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), Google scholar, SIGLE, the National Technical Information Service, the National Research Register (UK) and the Current Controlled Trials databases. The data for 2 outcomes (e.g., ophthalmopathy and recurrence) were independently extracted by 2 authors.A total of 4 RCTs were ultimately included. Radioiodine+prednisone therapy showed statistical significance in reducing the incidence of new or deteriorative ophthalmopathy comparing with the other 3 therapies. Compared with radioiodine, therapy with antithyroid drugs therapy as well as surgery significantly decreased the incidence of new or deteriorative ophthalmopathy. Radioiodine therapy significantly reduced the rate of recurrence when compared to therapy with antithyroid drugs or surgery. For decreasing the incidence of new or deteriorative ophthalmopathy, the 4 treatments were ranked as follows: radioiodine+prednisone therapy, therapy with antithyroid drugs, surgery and radioiodine therapy. For reducing the rate of recurrence, 3 treatments were ranked as follows: radioiodine therapy, therapy with antithyroid drugs and surgery.Radioiodine+prednisone therapy might have the least probability of leading to an exacerbation or new appearance of ophthalmopathy, and radioiodine therapy might have the least probability of causing a recurrence.


PubMed | The First Center Hospital of Tianjin
Type: | Journal: BMC cancer | Year: 2015

Liver transplantation is a treatment option for combined hepatocellular and cholangiocellular carcinoma (cHCC-CC) but its prognostic significance remains unclear. The present study aimed to evaluate the therapeutic effects of liver transplantation on cHCC-CC and analyze the clinicopathological factors affecting prognosis.Retrospective analysis of the clinicopathological data of a case series of 21 patients with cHCC-CC who underwent orthotopic liver transplantation from April 2000 to April 2011 was performed. Cumulative survival rate and tumor-free survival rate were calculated using the Kaplan-Meier method followed by the log-rank test.The operative survival rate of the 21 patients was 100%; the 30 day mortality was 4.8% (1/21) and 90-day mortality was 9.5% (2/21); 1-, 2-, 3-, and 5-year overall cumulative survival rates were 64%, 47%, 39%, and 39%, respectively; and the corresponding cumulative tumor-free survival rates were 64%, 37%, 30%, and 30%, respectively. Cumulative tumor diameter, lymph node metastasis, macroscopic portal vein tumor thrombus, and mixed states according to Allen typing were identified as the primary influencing factors of poor prognosis (all P<0.05).Liver transplantation may be an effective therapeutic method for the treatment of cHCC-CC. Strict screening of potential liver transplantation candidates with cHCC-CC can help reduce the risks of tumor recurrence and metastasis.


PubMed | The First Center Hospital of Tianjin
Type: Case Reports | Journal: Transplantation proceedings | Year: 2015

Splenic artery steal syndrome (SASS) has gained attention as a complication involving the hepatic artery and can cause ischemia in a grafted liver. This article presents 3 patients with SASS, including their diagnosis and treatment. Contrast-enhanced ultrasonography and angiography are useful in diagnosing SASS, and splenic artery trunk embolization is an effective treatment. The purpose of this article is to reinforce the understanding of the development and progression of SASS.

Loading The First Center Hospital of Tianjin collaborators
Loading The First Center Hospital of Tianjin collaborators